Conditions screened

    What a full-body MRI health check can detect, and what it cannot

    A system-by-system guide to what EVO's whole-body MRI, cardiac tests and 100+ blood and urine biomarkers look for, where each test is strong, and where screening has real limits.

    Updated

    A whole-body MRI can detect structural disease across the brain, neck, abdomen, pelvis, spine and joints, including many tumours, aneurysms, organ lesions, silent strokes and degenerative change. It does not see the lungs or coronary arteries well, which is why EVO adds CT calcium scoring, ECG, echo and mammography, and it cannot measure metabolic or hormonal health, which is why EVO adds 100+ biomarkers.

    How does EVO decide what to screen for?

    Screening is only useful if a finding changes what you do next. EVO's protocol, designed with 5C Network radiologists, concentrates on conditions that are common, serious, often silent in the early stage, and detectable with the right test. For each body system below we list what the Evo Core assessment looks for, which test does the work, and what it is known to miss.

    Every scan is read by a specialist radiologist with AI assistance, and every biomarker is interpreted alongside the imaging rather than in isolation. That combination is the difference between a list of findings and an understanding of your health.

    Which tests cover which body system?

    Evo Core components and the systems each one covers. Mammography is for women; the genetic module is optional.
    Body systemPrimary testWhat it looks forKnown limits
    Brain and nervous systemWhole-body MRI (brain sequences)Tumours, aneurysms, small-vessel disease, silent strokes, structural changeDoes not assess cognition directly; very small aneurysms may need dedicated angiography
    Heart and vesselsCT calcium scoring, ECG, 2D echo, lipid and glucose panelsCoronary plaque burden, rhythm and conduction, chamber size and pumping function, aortic and major-vessel abnormalities on MRICalcium scoring does not show soft, non-calcified plaque; a normal result lowers but does not remove risk
    Cancers and massesWhole-body MRI, mammography, tumour markersMasses in brain, neck, liver, kidneys, pancreas, adrenals, pelvis, bone and soft tissue; enlarged lymph nodes; breast lesionsWeak for lung, colon and skin cancers; small lesions can fall below resolution; markers are supportive, not diagnostic
    Liver, kidneys, pancreas, abdomenWhole-body MRI, liver and kidney blood panels, urineFatty liver, cysts and solid lesions, bile duct and gallbladder change, kidney stones and masses, spleen and adrenal findingsSmall bowel and stomach lining are poorly seen; endoscopy remains the test for the gut
    Spine, joints and muscleWhole-body MRIDisc degeneration and herniation, canal narrowing, vertebral lesions, joint effusion, muscle quality and symmetryWhole-body sequences are a survey; a symptomatic joint may need a dedicated scan
    Metabolic and hormonal100+ blood and urine biomarkersGlucose control, cholesterol fractions, kidney and liver function, thyroid, vitamin D and B12, inflammation, prostate and ovarian markersBlood values fluctuate; single readings are interpreted with your history and repeated when needed

    What can a full-body MRI detect in the brain?

    Brain MRI sequences can show tumours and other masses, aneurysms of the larger arteries, evidence of silent strokes and small-vessel disease, abnormal fluid spaces and structural change. These are findings that often have no symptoms until they are advanced, which is why imaging matters here.

    Silent strokes and white-matter change are more common than most people expect in middle age, and they are strongly tied to blood pressure, glucose and cholesterol, which the biomarker panel measures on the same day. When imaging and bloods point the same way, the roadmap prioritises vascular risk.

    MRI does not measure memory or cognition. If the scan shows change that could affect cognition, the report explains it and the concierge can arrange a neurology consultation.

    Can a full-body MRI detect heart disease?

    Not reliably on its own. Whole-body MRI can show the aorta and major vessels, but coronary artery disease, the leading cause of death in India, needs other tests. Evo Core therefore includes CT calcium scoring for plaque, a resting ECG for rhythm and conduction, and a 2D echocardiogram for heart structure and function.

    A coronary calcium score is one of the strongest predictors of future heart events in people without symptoms, and it is measured in minutes with a low-dose CT. Combined with LDL cholesterol, HbA1c and high-sensitivity CRP from the biomarker panel, it tells you whether to act now or simply keep tracking.

    The limit is soft plaque: calcium scoring sees calcified plaque only. A score of zero lowers risk substantially but does not remove it, and an abnormal result is a reason for a cardiologist review, not a diagnosis by itself.

    Which cancers can a whole-body MRI screen for?

    Whole-body MRI can show masses and abnormal tissue in the brain, head and neck, liver, kidneys, pancreas, adrenal glands, pelvis, bones and soft tissue, and enlarged lymph nodes. With mammography for women and tumour markers such as PSA, CA-125 and CA 19-9, EVO covers several common cancers at a structural and biochemical level.

    Three honest limits. First, MRI is poor at seeing the lungs, so lung cancer screening for current or former heavy smokers remains a low-dose chest CT decision with your doctor, in line with the US Preventive Services Task Force recommendation (2021). Second, early colon cancer and polyps are not visible on whole-body MRI; colonoscopy remains the standard. Third, tumour markers can be raised for benign reasons and normal in early cancer, so they support the imaging rather than stand alone.

    When a finding is suspicious, EVO's radiologists recommend the specific next test, for example a dedicated contrast MRI, ultrasound or biopsy, and the concierge arranges it quickly. The goal is to shorten the time between a question and an answer.

    What does the abdominal part of the scan show?

    Liver fat and lesions, gallbladder and bile duct change, kidney cysts, stones and masses, pancreatic and adrenal findings, and spleen size. Paired with liver and kidney blood panels and urine analysis, this is one of the most informative parts of the assessment for people with metabolic risk.

    Fatty liver is now one of the most common findings in Indian adults and is frequently silent. Seeing it on MRI, alongside raised liver enzymes or HbA1c, turns an abstract metabolic risk into a concrete target that is reversible with the right plan. For people on GLP-1 medication, the Evo GLP program tracks liver fat and visceral fat over time.

    The stomach lining and small bowel are not well assessed on whole-body MRI, so persistent digestive symptoms still call for endoscopy or dedicated imaging.

    What does EVO see in the spine, joints and muscles?

    Disc degeneration and herniation, narrowing of the spinal canal, vertebral lesions, joint fluid and cartilage change, and the volume and quality of major muscle groups. For athletes, the Evo S program extends this into detailed muscle volume, fat infiltration and left-right symmetry mapping.

    Many spinal findings are age-appropriate and need no action. The report says so plainly, which is as important as flagging the findings that do matter. A painful joint that was not the focus of the survey may still need a dedicated scan, and the radiologist will say when that is the case.

    What do the 100+ biomarkers detect that imaging cannot?

    Blood and urine reveal function: glucose control through fasting, post-meal and HbA1c values; cholesterol fractions and cardiometabolic risk; kidney filtration and liver enzymes; thyroid hormones; vitamin D and B12; systemic inflammation through high-sensitivity CRP; and prostate, ovarian and pancreatic tumour markers.

    These values change years before anything changes on a scan. Interpreted together with the imaging, they explain findings (a fatty liver with a high HbA1c), rule things out (a kidney cyst with perfect kidney function), and set the priorities in your roadmap. Because blood values fluctuate, EVO repeats key markers at the checkpoints in your year rather than relying on a single reading.

    What does a full-body MRI health check not detect?

    Lung nodules and early lung cancer, early colon cancer and polyps, skin cancer, coronary artery disease on MRI alone, stomach and small-bowel disease, cognition and mental health, and lesions smaller than the scanner's resolution. No screening program detects everything, and a clear report lowers risk without eliminating it.

    It is worth being direct about the evidence. A 2019 systematic review in the Journal of Magnetic Resonance Imaging found that roughly a third of asymptomatic adults who had a whole-body MRI had a finding that needed further clarification, most of which proved benign, and concluded that the evidence did not yet support whole-body MRI as routine population screening. The Cleveland Clinic (2026) makes a similar point: the benefit is early detection in some people, the cost is incidental findings and anxiety in others. An earlier review in the NIH's open-access library (2015) argued that whole-body MRI is most useful in defined groups rather than everyone.

    EVO is designed around that evidence rather than against it: radiologist grading of every finding, plain explanations of what is harmless, conservative follow-up intervals, a concierge who prevents a benign cyst from turning into a cascade of tests, and a biomarker layer that adds the functional information imaging lacks. It is a well-run screening program, not a promise of certainty.

    Who benefits most from this kind of screening?

    Adults from the mid-30s onwards, people with a family history of cancer, heart disease or diabetes, people with metabolic risk factors such as raised glucose or fatty liver, and people whose work or training puts unusual load on the body. If you already have symptoms, see a doctor first; targeted diagnosis is faster and more accurate than screening.

    For what each program includes and how booking works, see the pricing page. For preparation, safety and results questions, see the FAQ.

    Common questions about what EVO detects

    Can a full-body MRI detect cancer anywhere in the body?

    It can show masses and abnormal tissue in the brain, neck, liver, kidneys, pancreas, adrenal glands, pelvis, bones and soft tissue, and enlarged lymph nodes. It is poor for lung nodules, early colon cancer and skin cancer, and very small lesions can fall below its resolution. Any suspicious finding needs a targeted test to confirm.

    Why does EVO add CT calcium scoring, ECG and echo to the MRI?

    MRI is not a good screening tool for coronary artery disease, the leading cause of death in India. CT calcium scoring measures plaque in the heart arteries, the ECG checks rhythm and conduction, and the echocardiogram shows heart structure and pumping function. Together they cover what a whole-body MRI alone would miss.

    What are incidental findings and how common are they?

    Incidental findings are unexpected results such as small cysts, benign nodules or anatomical variants. Published studies of whole-body screening MRI report that a substantial share of healthy adults have at least one finding that needs clarification, and most turn out to be harmless. EVO radiologists grade each one and tell you whether to ignore, monitor or investigate.

    Does EVO replace colonoscopy, Pap smears or lung screening?

    No. Those are guideline screening tests with their own evidence and schedules. EVO complements them by covering organs and systems that routine screening does not image. Your report notes which guideline screenings are due for your age and risk, and the concierge can help arrange them.

    What do the 100+ blood and urine biomarkers add that imaging cannot?

    Blood and urine reveal function rather than structure: glucose control, cholesterol fractions, kidney filtration, liver enzymes, thyroid hormones, vitamin levels, inflammation and tumour markers. These catch metabolic and hormonal risk years before anything changes on a scan, and they give the imaging findings context.

    Is there a risk of over-diagnosis with whole-body screening?

    Yes, and it is the main criticism of whole-body MRI in healthy people: benign findings can lead to anxiety and extra tests. EVO manages this with radiologist grading, clear plain-language explanations, conservative follow-up intervals and a concierge who coordinates any further test, so a harmless finding does not become a cascade.

    Sources

    • Kwee RM, Kwee TC. Whole-body MRI for preventive health screening: a systematic review of the literature. Journal of Magnetic Resonance Imaging, 2019. PubMed
    • Cleveland Clinic Health Essentials. Is a full-body MRI worth it? Updated July 2026. health.clevelandclinic.org
    • Tarnoki DL et al. Clinical value of whole-body magnetic resonance imaging in health screening of general adult population. 2015. PMC
    • US Preventive Services Task Force. Lung cancer: screening. Final recommendation statement, 2021. uspreventiveservicestaskforce.org

    Medical disclaimer

    This page describes what screening tests can and cannot show in general terms. It is not medical advice and does not replace consultation with a qualified doctor. A normal screening result does not guarantee the absence of disease, and an abnormal result is not a diagnosis until confirmed by appropriate testing.